Christopher M. Bland

Clinical Professor, University of Georgia College of Pharmacy
  • University of Georgia College of Pharmacy
  • Authors
  • United States of America

About Christopher M. Bland

Dr. Christopher M. Bland is a Clinical Professor at the University of Georgia College of Pharmacy at the Southeast GA campus in Savannah, GA. Dr. Bland has over 20 years of academic and clinical experience in a number of clinical areas. He is a Fellow of both the Infectious Diseases Society of America as well as the American College of Clinical Pharmacy. He is co-founder of the Southeastern Research Group Endeavor, SERGE-45, with over 80 practitioners across 14 states involved. Dr. Bland serves as Associate Editor for the NAPLEX Review Guide 4th edition as well as Editor-In-Chief for the Question of the Week. He has provided live, interactive reviews for more than 10 Colleges/Schools of Pharmacy over the course of his career. 

Intro Content

Influencer Of

Popular Content

Recent Comments

Sep 11, 2022
Replying to Marina

Thanks for the question. Even E is correct, the first line says B is a correct answers, which letter says opposite 

It is corrected now thank you. 

Mar 12, 2021
Replying to Ahmed Shible

Hello Dr. Bland,

Doesn't methotrexate also suppress the immune system, and thus making the patient ineligible for both vaccines even before starting etanercept? or are the low doses of methotrexate used in RA not immunosuppressive like those used in chemotherapy?

Thanks so much for your strong work. I like your channel a lot and this how far back I have gone!

Hi Ahmed- You are correct in that for potent immunosuppressants this would be an issue. Since these are low doses of MTX (< 20mg weekly) they are generally okay. Hope this helps and thanks for your kind words. 

Jan 26, 2021
Replying to Faiyaz Patel

In above question, Levetricetam concentration expected drop by 50% with tryclcen(COC), in the question not only concer for reductions in COC concentration which can lead to pregnancy but reduction in concentration of Levetircetram which can lower seizure threshold. Here correct answer would be Divalperox because its non enzymes inducing class of AEDs. 

Hi Faiyaz- Thank you for your inquiry. I went back and rechecked for an interaction with levetiracetam and Ortho Tri Cyclen both within the package insert and using Lexi-Comp software. Both sources found no interaction between the two agents. Ortho tri cyclen can decrease serum concentrations of valproic acid (or divalproex) by approximately 18 and 29% so serum monitoring may be warranted. Therefore I will update this information in question. Thank you.

May 21, 2020
Replying to Matthew Stanton

Hi Dr. Bland,

I have some questions regarding this question.  Is naloxone available as inhalation? I'm not familiar with that product.  Perhaps I'm confusing dosage form vs route of administration?  For example, the injection can be used as inhalational therapy (off label), but it's a solution dosage form.  Same for the intranasal products which now there is a product available, but we used the solution for intanasal use for many years.  I may have the wrong thought process surrounding this.  Thank you.


Hi Matthew- Thank you for your question and very sorry for the delay in response as I'm just seeing this. I agree that the inhalation is more of an off-label usage and would not be the most appropriate answer as the exam mainly focuses on "on-label" uses. Therefore I'm going to modify this to just B and C. Thank you for your attention to detail!


Online Elsewhere